Adjuvant Therapy for High-risk Endometrial Carcinoma

Area of Science:

• Gynecologic Oncology
• Cancer Molecular Profiling
• Translational Cancer Research

Background:

• High-risk endometrial cancer (EC) presents a poorer prognosis, with limited survival improvements despite advances.
• Traditional clinicopathological factors for risk stratification show poor correlation with molecular profiles.
• Current management relies on surgery and radiotherapy, with limited survival benefit in early stages.

Purpose of the Study:

• To review current evidence on management strategies for high-risk endometrial cancer.
• To explore the evolving role of molecular diagnosis and stratification in treatment individualization.
• To assess the impact of adjuvant therapies based on molecular alterations.

Main Methods:

• Review of recent clinical trials and evidence on endometrial cancer management.
• Analysis of data comparing clinicopathological factors with molecular profiling for risk stratification.
• Evaluation of the role of adjuvant chemotherapy and radiotherapy in high-risk EC.

Main Results:

• Molecular profiling demonstrates superior discrimination for risk stratification compared to traditional factors.
• Chemotherapy shows benefit in more advanced stages and specific histological subgroups (e.g., Stage III).
• Early evidence suggests adjuvant chemotherapy benefit correlates with specific molecular alterations.

Conclusions:

• Personalized adjuvant treatment strategies are crucial for high-risk endometrial cancer.
• Molecular profiling is essential for accurate risk stratification and treatment individualization.
• Further research is needed to integrate molecular data into routine clinical decision-making for EC management.